S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
Log in

Five Prime Therapeutics Stock Forecast, Price & News

-1.74 (-10.90 %)
(As of 01/15/2021 12:00 AM ET)
Today's Range
Now: $14.22
50-Day Range
MA: $17.80
52-Week Range
Now: $14.22
Volume1.77 million shs
Average Volume807,350 shs
Market Capitalization$540.90 million
P/E RatioN/A
Dividend YieldN/A
Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase 3 clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that is in Phase 1a/1b clinical trial that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein, which is in Phase 1a/1b clinical trial that enhances co-stimulation of T cells through CD28. Its product candidates also include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with Opdivo. The company's BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in Phase 1/2 clinical trial as a single agent and in combination with Opdivo in patients with advanced malignant tumors. It has license and collaboration agreements with Bristol-Myers Squibb Company, GlaxoSmithKline LLC, INBRX 110 LP, UCB Pharma S.A., and Zai Lab (Shanghai) Co., Ltd.; and license agreements with Galaxy Biotech, LLC, BioWa, Inc. and Lonza Sales AG. The company was founded in 2001 and is headquartered in South San Francisco, California.
Five Prime Therapeutics logo


Overall MarketRank

1.68 out of 5 stars

Medical Sector

186th out of 1,556 stocks

Pharmaceutical Preparations Industry

90th out of 638 stocks

Analyst Opinion: 3.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:FPRX



Sales & Book Value

Annual Sales$14.87 million
Book Value$4.13 per share


Net Income$-137,200,000.00
Net Margins-554.71%


Market Cap$540.90 million
Next Earnings Date2/25/2021 (Estimated)
-1.74 (-10.90 %)
(As of 01/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive FPRX News and Ratings via Email

Sign-up to receive the latest news and ratings for FPRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Five Prime Therapeutics (NASDAQ:FPRX) Frequently Asked Questions

How has Five Prime Therapeutics' stock been impacted by Coronavirus?

Five Prime Therapeutics' stock was trading at $2.93 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, FPRX shares have increased by 385.3% and is now trading at $14.22.
View which stocks have been most impacted by COVID-19

Is Five Prime Therapeutics a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Five Prime Therapeutics in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Five Prime Therapeutics stock.
View analyst ratings for Five Prime Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Five Prime Therapeutics?

Wall Street analysts have given Five Prime Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Five Prime Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Five Prime Therapeutics' next earnings date?

Five Prime Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for Five Prime Therapeutics

How were Five Prime Therapeutics' earnings last quarter?

Five Prime Therapeutics, Inc. (NASDAQ:FPRX) posted its quarterly earnings results on Friday, November, 6th. The biotechnology company reported ($0.74) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.60) by $0.14. The biotechnology company had revenue of $2.05 million for the quarter, compared to analysts' expectations of $3.50 million. Five Prime Therapeutics had a negative return on equity of 75.84% and a negative net margin of 554.71%.
View Five Prime Therapeutics' earnings history

What price target have analysts set for FPRX?

7 Wall Street analysts have issued 12 month target prices for Five Prime Therapeutics' shares. Their forecasts range from $11.00 to $34.00. On average, they expect Five Prime Therapeutics' share price to reach $25.00 in the next twelve months. This suggests a possible upside of 75.8% from the stock's current price.
View analysts' price targets for Five Prime Therapeutics
or view Wall Street analyst' top-rated stocks.

Are investors shorting Five Prime Therapeutics?

Five Prime Therapeutics saw a increase in short interest during the month of December. As of December 31st, there was short interest totaling 1,140,000 shares, an increase of 26.8% from the December 15th total of 899,400 shares. Based on an average daily volume of 2,410,000 shares, the days-to-cover ratio is currently 0.5 days.
View Five Prime Therapeutics' Short Interest

Who are some of Five Prime Therapeutics' key competitors?

What other stocks do shareholders of Five Prime Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Five Prime Therapeutics investors own include Pfizer (PFE), Nektar Therapeutics (NKTR), OPKO Health (OPK), TG Therapeutics (TGTX), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Sangamo Therapeutics (SGMO), ImmunoGen (IMGN), VBI Vaccines (VBIV) and Mallinckrodt (MNK).

Who are Five Prime Therapeutics' key executives?

Five Prime Therapeutics' management team includes the following people:
  • Dr. Helen Louise Collins, Exec. VP & Chief Medical Officer (Age 57, Pay $637.25k)
  • Mr. Francis W. Sarena, Chief Strategy Officer & Sec. (Age 49, Pay $646.49k)
  • Mr. Thomas Civik, Pres, CEO & Director (Age 51)
  • Mr. David V. Smith M.B.A., Exec. VP & CFO (Age 60)
  • Mr. David White, Principal Accounting Officer (Age 56)
  • Mr. Martin Forrest, VP of Investor Relations & Corp. Communications
  • Dr. Nallakkan S. Arvindan, Sr. VP of Strategic Technology Operations

What is Five Prime Therapeutics' stock symbol?

Five Prime Therapeutics trades on the NASDAQ under the ticker symbol "FPRX."

How do I buy shares of Five Prime Therapeutics?

Shares of FPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Five Prime Therapeutics' stock price today?

One share of FPRX stock can currently be purchased for approximately $14.22.

How big of a company is Five Prime Therapeutics?

Five Prime Therapeutics has a market capitalization of $540.90 million and generates $14.87 million in revenue each year. The biotechnology company earns $-137,200,000.00 in net income (profit) each year or ($3.92) on an earnings per share basis. Five Prime Therapeutics employs 87 workers across the globe.

What is Five Prime Therapeutics' official website?

The official website for Five Prime Therapeutics is www.fiveprime.com.

How can I contact Five Prime Therapeutics?

Five Prime Therapeutics' mailing address is 111 Oyster Point Boulevard, South San Francisco CA, 94080. The biotechnology company can be reached via phone at 415-365-5600 or via email at [email protected]

This page was last updated on 1/18/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.